• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Nanotech derived from amniotic stem cells could help treat brain cancer

July 26, 2017 By Sarah Faulkner

Creative Medical Tech.Creative Medical Technology Holdings (OTC:CELZ) touted its exosome technology today, reporting that it demonstrated an ability to regenerate healthy brain cells while selectively halting the growth of glioma brain cancer cells in a preclinical model.

The company’s exosomes are vesicles harvested from amniotic stem cell technology, which it licensed from the University of California San Diego in an exclusive deal for the AmnioStem platform.

“Having seen first-hand the devastation and lack of treatment options in glioma patients, I am excited about the prospect of developing a non-toxic biological approach that eventually may provide benefit to this group of patients,” Dr. Santosh Kesari, a neuro-oncologist who previously worked at UCal San Diego, said in prepared remarks.

“The filed patent application contains data showing that while AmnioStem derived exosomes inhibited proliferation of glioma cells, other stem cell types actually increased proliferation of glioma,” chief scientific officer Thomas Ichim added.  “We are currently working under the possibility that AmnioStem stem cells may possess unique biological properties that are different from other types of stem cells.”

“From a commercialization perspective, exosomes are simpler to manufacture, store, and deliver as compared to living cells.  Additionally, since exosomes are not replicating cells, we anticipate a less complicated FDA regulatory pathway as compared to cellular based products,” president & CEO Timothy Warbington said.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Featured, Neurological, Oncology, Preclinical Trials, Stem Cells, Wall Street Beat Tagged With: creativemedicaltechnologyholdings, University of California San Diego

IN CASE YOU MISSED IT

  • Glucotrack to effect a reverse stock split
  • Medtronic unveils ‘MiniMed’ as name for soon-to-be separated Diabetes unit
  • Insulet, Marvel collab to unveil comic book hero with type 1 diabetes
  • Insulet rolls out new Omnipod 5 iPhone app for use with Dexcom G7
  • Tandem, Abbott strike deal to pair insulin pumps with glucose-ketone monitor

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS